Integrative pharmacogenomics revealed three subtypes with different immune landscapes and specific therapeutic responses in lung adenocarcinoma.

Xiaoyong Ge,Zaoqu Liu,Siyuan Weng, Hui Xu,Yuyuan Zhang,Long Liu,Qin Dang,Chunguang Guo,Richard Beatson,Jinhai Deng,Xinwei Han

Computational and structural biotechnology journal（2022）

Cited 2|Views11

No score

Abstract

We provided a novel molecular classification strategy and revealed three pharmacogenomics-based subtypes for LUAD patients, which uncovered potential subtype-related and patient-specific therapeutic strategies.

Translated text

Key words

CCLE, cancer cell cine encyclopedia,CTRP, cancer therapeutics response portal,DRGs, drug response-associated genes,GDSC, genomics of drug sensitivity in cancer,ICBs, immune checkpoint blockers,IGP, in-group proportion,Immune landscapes,LUAD, lung adenocarcinoma,Lung adenocarcinoma,Molecular subtypes,NMF, non-negative matrix factorization,NSCLC, non-small cell lung cancer,PI, proximal inflammatory,PP, proximal proliferative,PRISM, profiling of relative inhibition simultaneously in mixtures,Pharmacogenomics,Precision medication,SubMap, subclass mapping analysis,TMB, tumor mutation burden,TME, tumor microenvironment,TRU, terminal respiratory unit,Therapeutic responses,ssGSEA, single-sample gene set enrichment analysis

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined